News
Displaying 1–10 of 522
-
Ocugen Launches Phase 2/3 Clinical Trial for Stargardt Disease Gene-Modifier Therapy
Research NewsThe therapy delivers copies of the RORA gene to address multiple disease pathways.
-
Nanoscope Begins Rolling BLA Submission to FDA for Seeking Approval for its Optogenetic Therapy
Research NewsThe company plans to complete BLA submission in early 2026.
-
Atsena Gets FDA Nod to Expand XLRS Gene Therapy Clinical Trial to Include Pivotal Phase 3 Cohort
Research NewsThe expanded Phase 1/2/3 shortens time to potential FDA approval.
-
Retinitis Pigmentosa Research Advances
Research NewsRecent developments in research on retinitis pigmentosa.
-
Stargardt Disease Research Advances
Research NewsRecent developments in research on Stargardt disease.
-
Leber Congenital Amaurosis Research Advances
Research NewsRecent developments in research on Leber congenital amaurosis.
-
Age-Related Macular Degeneration Research Advances
Research NewsRecent developments in research on age-related macular degeneration.
-
Research News
In this in-depth interview hosted by InVivo, Jason Menzo, CEO of the Foundation Fighting Blindness, outlines the organization’s strategy for addressing significant changes and opportunities in the inherited retinal diseases (IRDs).
-
In the Press
Opus Genetics secures up to $2M in non-dilutive funding from the RD Fund to advance its OPGx-MERTK gene therapy program targeting retinitis pigmentosa caused by MERTK mutations.
